

April 28, 2015



Ceapro Appoints Seasoned Pharmaceutical Industry Executive, Ulrich Kosciessa, Ph.D., to its Board of Directors

EDMONTON, ALBERTA -- (Marketwired) -- 04/28/15 -- [Ceapro Inc. \(TSX VENTURE:CZO\)](#) ("**Ceapro**" or the "**Company**"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed international pharmaceutical industry expert, Ulrich Kosciessa, Ph.D., to its Board of Directors.

Glenn Rourke, MBA, Chairman of the Board of Ceapro, stated, "We are very pleased to welcome Dr. Kosciessa to the Board of Ceapro at this exciting time. Dr. Kosciessa brings a very extensive background in managing and building international pharmaceutical companies, invaluable scientific knowledge in product development, and experience in managing research groups. His appointment is very timely as we develop our therapeutic technology platform for beta glucan and avenanthramides into the expansive nutraceutical and pharmaceutical markets."

Dr. Kosciessa has over two decades of research, business development and marketing leadership experience. He is a member of the Executive Management Board of Medac GmbH, a global pharmaceutical company with operations in 70 countries, Managing Director of Medac International, and Chairman of the Board of Medac Pharma Inc., a U.S.-based subsidiary of Medac GmbH focused on specialty pharmaceuticals for autoimmune diseases and cancer. Throughout his successful management career at Medac, Dr. Kosciessa has formed several subsidiaries and affiliates as well as established a network of global partners, growing the company's international business more than 50% since 2005.

In addition, since 2006 Dr. Kosciessa has also served as Chief Executive Officer of Photonamic, a subsidiary of Medac GmbH focused on research and development of photodynamic therapy and diagnostics. He has successfully developed two Photonamic products currently marketed in Europe, South America and the AsianPacific region plus Australia. From 2006 to 2008, Dr. Kosciessa also served as Chief Executive Officer at Immune Laboratory of Hannover, a research-based organization focused on autologous dendritic cell-based tumor vaccines.

Dr. Kosciessa commented, "It is my great pleasure to join the Ceapro Board of Directors at this important time as the company expands its natural ingredient product expertise into additional potential therapeutic indications. In addition to Ceapro's leading, proprietary expertise in extracting two essential pharmaceutical grade active ingredients, avenanthramides and beta glucan, I am also quite excited with the development of its enabling technologies like the **Pressurized Gas eXpansion** technology which has the

potential for a broad spectrum of applications in our industry."

Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, added, "We are honored to have an expert like Dr. Kosciessa joining our Board. We firmly believe Dr. Kosciessa's scientific and business acumen combined with his successful business development track record and vast industry network will prove to be invaluable as we prepare for our next phase of growth."

Prior to joining Medac GmbH, Dr. Kosciessa was a postdoctoral researcher at the neuroscience/neurodegenerative diseases division of Schering AG, a multinational pharmaceutical company. He received a B.S. in Biology and a Ph.D. in Molecular Biology from Georg-August University of Göttingen, Germany.

Dr. Kosciessa was granted options to purchase 150,000 common shares, each with an exercise price according to TSX-V regulations. Each grant vests in three equal installments, the first of which vests immediately with the second and third instalments vesting on the first and second anniversaries of the date of grant. Each option is exercisable, once vested, for a period of ten years from the date of grant.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INVESTOR/MEDIA CONTACT: Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): 908-938-1475
E: jenene@jenenethomascommunications.com

Source: Ceapro Inc.